Max Macaluso
TMFMassimo
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Recent Articles by Max Macaluso
Dec 13, 2012
by Max Macaluso
The Best of 2012: Affymax
Affymax's drug treating anemia in dialysis patients was FDA approved this year, and is now a major threat to the competition. That has shares up nearly 270% for the year, making Affymax #11 on our list of the very best healthcare stocks of 2012.
Dec 7, 2012
by Max Macaluso
Amarin Throws a Curveball
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.